Table 1.
Antibacterial and antiviral activities of glycopeptide aglycons and their derivatives (Printsevskaya et al., 2005) (See Fig. 4)
| Compound | MICa (μg/ml) |
IC50b (μM) |
EC50c (μM) |
|||||
|---|---|---|---|---|---|---|---|---|
| 533 S. epider-midis | 559 E. faecalis (GSE) | 560 E. faecalis (GRE) | L1210 | MOLT-4/C8 | CEM | HIV-1 | HIV-2 | |
| Vancomycin aglycon and its amide | ||||||||
| 11 | 4 | 2 | >64 | >500 | >500 | >500 | 65 | ≥250 |
| 11a | 2 | 1 | 16 | ≥250 | 72 | ≥250 | 3.0 | 9.5 |
| Eremomycin aglycon and its amide | ||||||||
| 12 | 32 | 16 | >128 | >500 | >500 | >500 | 50.6 | ≥250 |
| 12a | 8 | 4 | 8 | 94 | 126 | 148 | 1.6 | 7 |
| Des-(N-d-MeLeu)-vancomycin aglycon and its amide | ||||||||
| 13 | >128 | >128 | >128 | ≥250 | ≥250 | >250 | ≥125 | ≥125 |
| 13a | >32 | >64 | >64 | ≥250 | 178 | ≥250 | 20 | 30 |
| Des-(N-d-MeLeu)-eremomycin aglycon and its amide | ||||||||
| 14 | >128 | >128 | >128 | >250 | >250 | >250 | 115.2 | >250 |
| 14a | >32 | >64 | >64 | 175 | >250 | >250 | 5.5 | 3.5 |
a
Minimum inhibitory concentration of the compound. As MWs of all compounds are in the interval ∼1000–1400 Da and MICs values given in “μg/ml” are very close to those calculated in “μM”.
b
Inhibitory concentration, or compound concentration required to inhibit cell proliferation by 50%.
c
Effective concentration or concentration required to protect cells against the cytopathicity of the different HIV strains by 50%.